MNTA 'ReadMeFirst' updated:
Sanofi “un-launches” Lovenox authorized generic;
NVS-MNTA contract has no provision to revert to pre-AG mode;
table of monthly branded and generic Lovenox scripts;
chronology of Lovenox pricing changes Sep 2011 to present;
appeal of Lovenox PI scheduled for 1/24/12;
FDA approves NVS/MNTA’s vial formulation of Lovenox;
2012-2013 news flow (new info re appeal of Lovenox PI);
transcript of Deutsche Bank webcast (12/5/11);
handicapping the Copaxone ANDA (revised);
MNTA acquires ‘sialic switch’ IP from Virdante Pharmaceuticals;
musings on the Virdante acquisition;
US patent-expiration dates for large-selling biologics;
recent patent applications and overview of IP estate;
new version of “What’s New in the Anticoagulant Arena?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=69823153